--- Query Results ---

  
Program:Genetics and Genomics
 
Test Name:MLH1 Promoter Hypermethylation
Performing Site: University of Alberta Hospital
Performing Dept:Molecular Pathology
 
Availability:Test performed every three weeks.
TAT:1 month
 
Preferred Tube/Container:See Specimen Requirements
 
Specimen Requirements: For Paraffin-Embedded Tissue:
1. Representative formalin-fixed, paraffin-embedded tissue block of tumor tissue is preferred.
2. Alternatively, one slide stained with Hematoxylin & Eosin as well as five 10-micron
   non-baked unstained slides can be submitted.
3. Please provide a copy of the corresponding pathology report.
 
Requisition/Form:All requests MUST be submitted on a Molecular Pathology Requisition.
Please provide any pertinent clinical history on the requisition.
 
Indications:MLH1 promoter hypermethylation testing distinguishes sporadic MSI-High tumors from tumors with germline mutations in the MLH1 mismatch repair gene (Lynch Syndrome).
Gene:MLH1
 
Method:Bisulfite modification, PCR followed by capillary electrophoresis.
Method Details:The methylation specific PCR assay is a modification of the method described by Grady et al. (Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-902). The analytical sensitivity of the assay is 1%. The test involves extraction of DNA from FFPE or peripheral blood using the QIAsymphony DSP DNA Mini Kit from Qiagen (Valencia, CA.), PCR amplification and capillary electrophoresis

PCR-based assays for the detection of hypermethylation of the MLH1 promoter region and BRAF V600E mutation. The methylation specific PCR assay is a modification of the method described by Grady et al. (Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-902). The analytical sensitivity of the assay is 1%. The tests involves extraction of DNA from FFPE or peripheral blood using the QIAsymphony DSP DNA Mini Kit from Qiagen (Valencia, CA.), PCR amplification and capillary electrophoresis.
 
 
Last Updated On:Tuesday, June 4, 2019
Date of Last Review:Jan 2 2018 12:00AM